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Abstract
Slits are a group of secreted glycoproteins that play a role in the regulation of cell migration. Previous studies sug-
gested that Slit2 might be a tumor-suppressor gene. However, it remained to be determined whether Slit2 sup-
pressed tumor growth and metastasis in animal models. We showed that Slit2 expression was decreased or
abolished in human esophageal squamous cell carcinomas (SCCs) compared to normal tissues by in situ hybridi-
zation. Stable transfection of human SCC A431 and fibrosarcoma HT1080 cells with Slit2 gene suppressed tumor
growth in athymic nudemice. Apoptosis in Slit2-transfected tumors was increased, whereas proliferating cells were
decreased, suggesting a mechanism for Slit2-mediated tumor suppression. This was supported by further analysis
indicating that antiapoptotic molecules Bcl-2 and Bcl-xl and cell cycle molecules Cdk6 and Cyclin D1 were down-
regulated in Slit2-transfected tumors. Furthermore, wound healing and Matrigel invasion assays showed that the
transfection with Slit2 inhibited tumor cell migration and invasion. Slit2-transfected tumors showed a high level of
keratin 8/18 and a low level of N-cadherin expression compared to empty vector–transfected tumors. More impor-
tantly, Slit2 transfection suppressed the metastasis of HT1080 tumor cells in lungs after intravenous inoculation.
Collectively, our study has demonstrated that Slit2 inhibits tumor growth and metastasis of fibrosarcoma and
SCC and that its effect on cell cycle and apoptosis signal pathways is an important mechanism for Slit2-mediated
tumor suppression.
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Introduction
Slits are secreted proteins that regulate axon guidance, branching, and
neuronal migration during development of the central nervous system
[1–5]. The Slit gene family consists of three genes, Slit1, Slit2, and
Slit3. All are expressed in the nervous system but Slit2 and Slit3 can
also be found in other tissues such as skin, lungs, and lymphoid organs
[6,7]. Slits are ligands for transmembrane receptors, the Robo (round-
about) gene family [8]. The interaction of Slits with Robos plays im-
portant roles in the regulation of cell migration in brain development
and inflammatory responses [6,7,9].
Abbreviations: Robo, roundabout proteins; RT-PCR, reverse transcription–polymerase
chain reaction; SCC, squamous cell carcinoma
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A number of studies have demonstrated that Slit2 is epigenetically
silenced in lung, breast, cervical, and colon cancers [10–13]. Ectopic
expression of Slit2 suppresses colony formation of tumor cells in aga-
rose cultures. The conditioned medium from Slit2-transfected cells re-
duces cell growth and induces apoptosis of colorectal carcinoma cell
lines, implicating that Slit2 has tumor-suppressor activities [12]. How-
ever, some reports indicated that Slit2 expression was increased
in prostate cancer, malignant melanoma, rectal mucinous adenocar-
cinoma, invasive breast carcinoma, gastric cancer, and hepatocellu-
lar carcinoma [14,15]. Moreover, it was reported that tumor-derived
Slit2 enhanced tumor angiogenesis, whereas neutralization of tumor-
derived Slit2 suppressed human melanoma growth in animals [15].
Several issues remain to be determined. First, Slit2 is also expressed
in normal tissues and its expression level can be increased by inflam-
mations [6]. Because inflammations are commonly present in many
tumors, the expression level of Slit2 in tumor samples, which may in-
clude normal tissues, may not be directly related to the expression of
Slit2 by tumor cells, as assessed by reverse transcription–polymerase
chain reaction (RT-PCR) and Western blot analyses. Second, it is un-
known whether Slit2 suppresses tumor growth in animal models, al-
though Slit2 has been reported to inhibit the colony formation of
tumor cells in cultures. Last, neutralization of Slits in the animal ex-
periments might block not only the effect of tumor-derived Slit2 but
also the endogenous Slit2 produced by normal tissues and cells [15]. It
might lead to additive effects, which complicate the interpretation for
the effect of tumor-derived Slit2.
A recent article reported that Slit2 inhibited CXCR4-mediated
migration of breast cancer cells, suggesting that Slit2 may regulate
tumor invasion and metastasis [16]. Another report showed that
Slit2 suppressed the invasion of medulloblastoma cells [17]. How-
ever, it remains to be proven whether Slit2 affects tumor metasta-
sis in vivo.
In the current study, we examined the Slit2 expression in human
esophageal cancers including adenocarcinoma and squamous cell car-
cinoma (SCC) by in situ hybridization to directly compare Slit2 ex-
pression level in normal and cancerous tissues. To examine the effect
of Slit2 on tumor development, Slit2 gene was stably transfected
into the human fibrosarcoma HT1080 and SCC A431 cells that
were originally negative for Slit2. In vitro and in vivo data showed
that Slit2 suppressed tumor growth and metastasis of human fibro-
sarcoma and SCC. In addition, further experiments indicated that
Slit2-mediated effects on cell cycle, proliferation, and apoptosis signal




Tissue specimens included a total of 211 tumor samples: 95 esoph-
ageal SCCs and 116 esophageal adenocarcinomas. Some of the tu-
mor samples included adjacent or distant normal tissues; that is,
there were 66 cases of normal esophageal mucosa. These samples
were obtained from the Department of Pathology, University of
Texas M. D. Anderson Cancer Center and from InnoGenex (San
Ramon, CA). All samples were routinely fixed in 10% buffered
formalin, embedded in paraffin, and cut into 4-μm sections. Tu-
mor samples were stained with hematoxylin and eosin (H&E) for
classification. Our institutional review board has approved a proto-
col for the use of the patient samples in an anonymous fashion for
the study.
In Situ Hybridization
To detect Slit2mRNA expression level, a nonradioactive in situ hy-
bridization was performed as described previously [6,18]. Briefly, Slit2
cDNA fragment between 955 and 1685 bp was cloned into pGEM
vector (Promega, Madison, WI). The plasmid was linearized by Apa I,
and digoxigenin-labeled sense and antisense cRNA were generated
by using SP6 polymerase in the presence of digoxigenin-UTP. Human
retinoid X receptor-α (RXR-α) was used as a positive control for the
intact tissue mRNA as described previously [18]. For in situ hybridi-
zation, the tissue sections were treated with 0.2 N HCl and proteinase
K, respectively, after deparaffinization and rehydration. The slides were
then postfixed with 4% paraformaldehyde and were acetylated in
freshly prepared 0.25% acetic anhydride in a 0.1-M triethanolamine
buffer. The slides were then prehybridized at 42°C with a hybridization
solution containing 50% deionized formamide, 2× standard saline cit-
rate (SSC), 2× Denhardt’s solution, 10% dextran sulfate, 400 μg/ml
yeast tRNA, 250 μg/ml salmon-spermDNA, and 20mMdithiothreitol
in diethylpyrocarbonate-treated water. Next, the slides were incubated
in 50-μl per slide hybridization solution containing 20 ng of a freshly
denatured dig-cRNA probe at 42°C for 4 hours. The slides were washed
for 2 hours in 2× SSC containing 2% sheep serum and 0.05% Triton
X-100 and then for 20 minutes at 42°C in 0.1× SSC. For color reac-
tion, the slides were incubated for 30 minutes at room temperature in
0.1 M maleic acid and 0.15 M NaCl containing 2% sheep serum and
0.3% Triton X-100 and then incubated overnight at 4°C with a sheep
anti-digoxigenin antibody. After washing, color was developed in a
solution containing 45 μl of nitroblue tetrazolium and 35 μl of an X-
phosphate solution in 10 ml of buffer, which consisted of 0.1 M Tris,
0.1 M NaCl, and 0.05 MMgCl2 (pH 9.5) for 4 hours. The slides were
then mounted with cover glass in Aqua mounting medium (Fisher,
Houston, TX).
Section Review and Statistical Analysis
The stained sections were assigned as having positive or negative
staining. Positive staining was defined as 10% or more of the epithe-
lial cells stained positively. Statistical analysis was performed using the
χ 2 test to determine the association between normal and tumor tis-
sues. The differences between normal and cancerous tissues were an-
alyzed using χ 2 test with Statistica (version 4.01) for PowerMac
computer (StatSoft, Tulsa, OK).
Cell Culture and Transfection
The human fibrosarcoma HT1080 and SCC A431 cell lines were
obtained from the American Type Culture Corporation (Manassas,
VA) and cultured in minimum essential medium and Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum, respectively. The plasmids encoding
the full-length human Slit2 with a cMyc tag and empty control vec-
tor were reported in previous studies [6,19]. To establish stable trans-
fectants of tumor cells, the Slit2 and control plasmids were transfected
into HT1080 and A431 cells by electroporation using Nucleofector
II (Amaxa, Cologne, Germany) according to the manufacturer’s in-
struction. The human Slit2–transfected cells (HT1080/Slit2, A431/
Slit2) and the control vector–transfected cells (HT1080/Vector,
A431/Vector) were selected in cultures with graded concentrations
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of G418 (0.5-1.5 mg/ml). Stable transfectants were analyzed for the
expression of Slit2 by RT-PCR and Western blot analyses.
Reverse Transcription–Polymerase Chain Reaction Analysis
The expression of Slit2 and Robo4mRNA in parental and transfected
cells was determined by RT-PCR. Briefly, total RNA was isolated from
tumor cells using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instruction. First-strand DNA was synthesized using
an Omniscript Reverse Transcriptase kit (Qiagen, Valencia, CA) accord-
ing to the instructions. The cDNA was then subjected to PCR ampli-
fication with the PLATINUM.PCR Supermix kit (Invitrogen). The
following primers for human genes were used in the studies: Slit2: 5′-
gacgactgccaagacaacaa-3′ and 5′-tgatagccaggcaaacactg-3′; Robo4: 5′-
aaccacttctcctgtccacc-3′ and 5′-tcctccacttcctgtgatcc-3′. Reactionmixtures
were subjected to the following amplification protocol: 1 cycle at 94°C
for 4minutes and 30 cycles at 94°C for 45 seconds, 58°C for 30 seconds,
and 72°C for 60 seconds. The PCR products were separated by aga-
rose gel electrophoresis, and the results were analyzed using a gel docu-
mentation system (Bio-Rad Laboratories, Hercules, CA). As controls,
RNA samples without reverse transcription were subject to PCR to ex-
clude DNA contamination.
Western Blot
To detect Slit2 proteins, parental HT1080, A431, and transfected
cells were cultured until confluent. Cell culture supernatants were
collected and filtered with a 0.22-μm filter. Samples were loaded onto
7.5% SDS-PAGE and then transferred to nitrocellulose membranes.
The membranes were blocked for 1 hour with phosphate-buffered
saline containing 5% nonfat dry milk and 0.1% NP-40. The mem-
branes were probed with anti-cMyc (9E10) monoclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA). After washing, the blots
were incubated with appropriate horseradish peroxidase–linked sec-
ondary antibodies. Protein bands were revealed by an enhanced chemi-
luminescence system (Pierce Biotechnology, Rockford, IL).
To detect levels of Cdk6, Cyclin D1, and Bcl-xl in tumor tissues,
tumor samples were harvested and ground in the RIPA buffer. Tu-
mor lysates were subjected to Western blot using anti-Cdk6 (B-10),
anti–Cyclin D1 (HD11; Santa Cruz Biotechnology), and anti–Bcl-xl
antibodies (Cell Signaling, Danvers, MA). Blots were quantified
using Quantity one 1-D Analysis Software (Bio-Rad Laboratories).
The relative expression level of proteins was normalized to GAPDH
in each sample.
Colony Formation Assay
Tissue culture plates (six-well plates) were precoated with 0.5%
low–melting point agarose. Tumor cells were suspended in 0.35%
agarose and were placed on top of the precoated agarose. After the aga-
rose was solidified, 2 ml of complete growth medium was overlaid,
and plates were incubated at 37°C in 5% CO2. Cells were fed weekly
with complete growth medium. The number of colonies was counted
microscopically approximately 3 weeks after culture.
Tumor Growth in Animals
Female athymic nude mice, 6 to 8 weeks old, were purchased from
Frederick Cancer Research (Frederick, MD). Mice were injected sub-
cutaneously with 2 × 106 HT1080 cells that were suspended in 50%
Matrigel or 1 × 106 A431 in 30%Matrigel (BD Biosciences, San Jose,
CA). Tumor growth was measured every 3 to 4 days using electronic
calipers. Tumor volume was calculated as follows:
Tumor volume ¼ L  S  H  π=6 ðL: long diameter;
S : short diameter;H : heightÞ
TUNEL Assay
Tumor samples were fixed in 10% formalin and sections (5 μm)
were made. TUNEL assay was performed using a commercial apop-
tosis detection kit (Promega) according to the manufacturer’s in-
struction. Sections were counterstained with DAPI, mounted, and
photographed microscopically with a 10× objective. For negative con-
trol purposes, TdT enzyme was omitted from the reaction mixture.
Samples treated with DNase I served as positive controls. The number
of apoptotic cells was counted microscopically, and results from five
fields of each group were calculated for statistical analysis.
Immunohistochemical Staining
Tumors tissues were fixed in formaldehyde and embedded in paraf-
fin. Sections (7 μm) were cut by a Microtome, deparaffinized, and re-
hydrated as routines. Briefly, tissue sections were first incubated with
blocking buffers to avoid nonspecific binding of antibodies and then
incubated with antibodies specific to proliferating cell nuclear anti-
gen (PCNA; sc-9857), E-cadherin (sc7870), N-cadherin (sc-7939),
Bcl-2 (sc-783), and Ck8/18 (MS-977; Santa Cruz Biotechnology).
Proliferating cell nuclear antigen–positive cells were detected by a
peroxidase-coupled secondary antibody (Pierce) and visualized with
Fast 3′3-Diaminobenzidine Tablet Set (Sigma, St. Louis,MO). Sections
were counterstained with H&E. Alexa Fluor 594–coupled secondary
antibody (Invitrogen) was used to detect the other molecules. Sections
were counterstained with a fluorescence DNA dye DAPI. Results
were evaluated and pictures were taken microscopically with a digital
camera using software from the manufacturer (Olympus, Pittsburgh,
PA). The percent of PCNA-positive cells (PCNA+/total cells per field)
was analyzed statistically from results of 10 fields in each sample.
Wound Healing Assay
Tumor cells were synchronized in serum free medium for 24 hours
after confluence. The monolayers of cells were wounded by manual
scratching with a 200-μl pipette tip, washed with PBS, placed in
complete growth medium, and photographed with a digital camera
connected to a phase-contrast microscope (4× objective). Matched
pair-marked wound regions were photographed again after 6 hours.
The distance of the scratch at the same position was measured by
using the Image-Pro Plus software (4 points per well and 3 wells per
sample, total measurement points: 12 points per sample). The mi-
gration index was calculated by the following formula: % Migration =
(the length of initial wound − the length of wound after 6 h) × 100/the
length of initial wound.
Matrigel Invasion Assay
Tumor cell invasion was measured with a Biocoat Matrigel invasion
chamber (Becton Dickinson Labware, Bedford, MA) according to the
manufacturer’s instructions. Briefly, tumor cells (2.5 × 104) in 0.5 ml
of DMEMcontaining 0.1% BSAwere seeded into the upper chamber,
which had Matrigel-coated membrane, and 0.75 ml of DMEM con-
taining 10% fetal bovine serum was added into the lower chamber.
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Epidermal growth factor was added as a chemokine in the lower cham-
ber at 1 ng/ml in the assay for A431. After incubating for 24 hours
at 37°C, membranes were collected and noninvading cells were re-
moved from the upper surface of the membrane using a cotton swab.
The membranes were then fixed with methanol, stained with 0.1%
crystal violet, and photographed microscopically with a 10× objective.
The number of invaded cells on the lower surface of the membrane
was counted in 20 fields of four wells (HT1080) or 40 fields of four
wells (A431).
Tumor Metastasis in Lungs
One million of parental, control vector–transfected, or Slit2-
transfected HT1080 cells were injected intravenously in athymic
nude mice through the tail vein. Five weeks after tumor injection,
mice were killed and lungs were collected. Lungs were inflated and
fixed in alcoholic formalin (10% of formalin and 63% of alcohol).
Paraffin-embedded tissues were step-sectioned and sections were
stained with H&E. Metastatic tumor nodules in the lungs were
counted microscopically (24 sections of eight mice per group). The
diameter of tumor nodules was measured with the Image-Pro Plus
software (14 images of HT1080, 17 images of HT1080/Vector,
and 5 images of HT1080/Slit2).
Statistical Analysis
All experiments were performed in at least three independent as-
says, which yielded comparable results. Data are summarized as
means ± SEM. Statistical analysis of the results was performed by
Student’s t test for unpaired samples. P < .05 was considered statis-
tically significant.
Results
Expression of Slit2 Is Reduced in Human Esophageal Cancers
The expression level of Slit2 mRNA was examined in a total 211
cases of human tumor specimens and 66 cases of normal counterpart
tissues by in situ hybridization. Slit2 was expressed in 83.3% (55/66)
of normal esophageal mucosa, whereas its expression was significantly
reduced in esophageal (92/211, 43%) cancers. Statistical analysis
showed that the difference is significant between normal and esoph-
ageal SCC tissues (P = .00001). A representative figure (Figure 1A)
shows that the adjacent normal tissues express a higher level of Slit2
than the cancerous tissues. We did further statistical analyses on the
esophageal cancers, including sex, age, pathologic stage, lymph node
and distant metastasis, tumor location, size, and differentiation of
adenocarcinoma, SCC, and the combination. A statistically signifi-
cant correlation was found between Slit2 expression with tumor dif-
ferentiation status of SCC (P = .0025). These data indicate that the
expression of Slit2 is inhibited in human esophageal cancers.
Human fibrosarcoma HT1080 and SCC A431 cells did not express
Slit2 mRNA but did express Robo4, one of membrane ligands for
Slit2 (Figure 1B). To evaluate the role of Slit2 on tumors, HT1080
and A431 cells were transfected with a vector-encoding human Slit2
gene or the empty control vector without insertion of Slit2 gene. Stable
Figure 1. Expression of Slit2 mRNA in normal and malignant esophageal tissues. (A) Slit2 mRNA was detected by in situ hybridization
using digoxigenin-labeled antisense cRNA and positive cells are blue (Pos Ctrl). Sense cRNA was used as a negative control (Neg Ctrl).
The normal esophageal epithelium (N) and SCC (Ca) are shown on the same section. Pictures were taken microscopically with a 10×
objective. (B) Transcriptions of Slit2 and Robo4 in tumor cell lines HT1080 and A431 were detected by RT-PCR. The sample order of each
cell line is parental, control vector–transfected, and Slit2-transfected cells. (C) Detection of cMyc-tagged Slit2 proteins. Slit2 proteins in
culture supernatants of parental and transfected tumor cell lines were detected by Western blot using an anti-cMyc antibody. The super-
natant of Slit2-transfected HK293 (HK293/Slit2) cells served as a positive control.
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transfectants with Slit2 gene (HT1080/Slit2, A431/Slit2) or the
control vector (HT1080/Vector, A431/Vector) were established in a
selection medium containing G418. The expression of Slit2 mRNA
was confirmed by RT-PCR. The Slit2 proteins in culture supernatants,
which were tagged with a cMyc fragment, were detected by Western
blot using a monoclonal antibody against cMyc (Figure 1C ). The su-
pernatant of Slit2-transfected 293 cells, which was reported in previous
studies [6,19], was used as a positive control.
Slit2 Inhibits Tumor Growth
To examine the effects of Slit2 on the anchorage-dependent growth
of tumor cells, parental and Slit2- or control vector–transfected tumor
cells were cultured in tissue culture plates, and cell growth was evalu-
ated by cell counting and ATPLite assay (PerkinElmer Life and Ana-
lytical Sciences, Boston, MA). No significant difference was observed
between the tumor cells (data not shown). To determine the effect of
Slit2 on the anchorage-independent growth, the tumor cells were cul-
tured in soft agar, and colony formation wasmeasured in six-well plates
(Figure 2A). Parental and control vector–transfected HT1080 cells
had 77.5 ± 2.5 and 91.5 ± 1.5 colonies per well, respectively, whereas
Slit2-transfected HT1080 cells formed 26 ± 3.0 colonies per well.
Similarly, Slit2-transfected A431 cells had 29.33 ± 1.76 colonies per
well compared to 132 ± 2.08 and 169 ± 4.04 colonies per well in cul-
tures of parental and control vector–transfected A431 cells, respectively.
The difference in the number of colonies is significant between Slit2-
transfected and parental or control vector–transfected tumor cells (P <
.01). These data demonstrate that Slit2 inhibits tumor cell growth in an
anchorage-independent manner.
To test whether Slit2 inhibits tumor growth in vivo, parental, con-
trol vector–, or Slit2-transfected HT1080 and A431 cells were injected
subcutaneously in athymic nudemice (four to fivemice per group) and
tumor growth was measured (Figure 2, B and C ). Slit2 transfection
significantly inhibited the growth of HT1080 and A431 tumors. At
23 days after injection, the volumes of parental and control vector–
transfected HT1080 tumors reached 619.39 ± 130.4 and 600.43 ±
144.6 mm3, respectively. However, the volume of Slit2-transfected
HT1080 tumors was only 64.25 ± 21.68 mm3 at the same time
(Figure 2B). About a quarter of mice, which were injected with
Slit2-transfected HT1080 cells, developed visible necrosis when the
tumor volume reached approximately 400 mm3 at 34 days after injec-
tion. Thereafter, the tumor size shrank. Similar results were observed
in mice that were injected with parental, control vector–, or Slit2-
transfected A431 tumor cells (Figure 2C ). At 21 days after injection,
the tumor volume of mice injected with Slit2-transfected A431 cells was
201 ± 162 mm3 compared to 762.7 ± 160.3 and 1257 ± 205.7 mm3 in
tumors of mice injected with parental and control vector–transfected
A431 cells, respectively (P < .05). These results indicate that the forced
expression of Slit2 inhibits tumor growth in animal models and support
that Slit2 has tumor-suppressor effects on fibrosarcoma and SCC.
Slit2 Enhances the Apoptosis of Tumors
The regulation of apoptosis and angiogenesis has been suggested
for Slit2-mediated effects on tumors [12,15]. Our initial experiments
did not show a significant difference in apoptotic cells between Slit2-
transfected and control cells in cultures, as assessed by staining with
Annexin V and 7-AAD in a flow cytometer (data not shown). It was
not in consistent with the report, which showed Slit2-mediated apop-
tosis of tumor cells in cultures [12]. However, a significantly higher
number of apoptotic cells was observed in Slit2-transfected HT1080
tumors than in the control tumors, which were collected from nude
mice (Figure 3A). In a further analysis of tumor lysates, antiapoptotic
Bcl-xl and cell cycle signal molecules Cdk6 and Cyclin D1 were found
to be down-regulated in Slit2-transfected HT1080 tumors compared
to the controls (Figure 3, B and C ). These data implicate that Slit2-
mediated regulation of apoptosis and cell cycle signal pathways are im-
portant mechanisms for its tumor-suppressive effects. A significant
change in the density of blood vessels was not observed between Slit2-
transfected and control HT1080 tumors by immunohistochemical
staining with anti-CD31 antibodies (data not shown).
Slit2 Inhibits Tumor Metastasis
Increased cell motility is associated with malignancy and metas-
tatic potential of tumor cells [20]. There were reports indicating
that Slit2 inhibited the migration of tumor cells in vitro [16,17]. To ex-
amine whether Slit2 inhibited tumor metastasis, in vitro and in vivo
experiments were conducted with the Slit2-transfected HT1080 and
A431 tumor cells.
Figure 2. Slit2 inhibits tumor growth. (A) Slit2 transfection inhibits
colony formation of HT1080 and A431 cells in soft agar cultures. In
the assessment of tumor growth in vivo, tumor cells were injected
subcutaneously in athymic nude mice, and tumor growth was
monitored. Transfection with Slit2 suppresses tumor growth of
HT1080 (B) and A431 (C). Tumor volume is calculated as length ×
width × height × 0.63. Data are shown as mean ± SEM of four to
five mice per group. *P < .05.
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In a wound healing assay that measures cell migration, Slit2 trans-
fection significantly inhibited the migration of tumor cells compared
to the controls (Figure 4A). In further experiments that examined the
invasiveness of tumor cells, we found that parental and control vector–
transfected tumor cells efficiently penetrated the Matrigel-coated mem-
brane, whereas the penetration rate of Slit2-transfected tumor cells was
significantly reduced (Figure 4B). Identical results were observed with
both HT1080 and A431 tumor cells, implicating that Slit2 inhibits
the migration and invasiveness of both tumor cells.
To further determine the effect of Slit2 on tumor metastasis in vivo,
parental, control vector–, or Slit2-transfected HT1080 cells were in-
jected intravenously in athymic nude mice [21]. Pulmonary metastatic
nodules were found in six of eight and in all seven mice that were
injected with parental and control vector–transfected HT1080 cells, re-
spectively. In contrast, four of eight mice that were injected with Slit2-
transfected HT1080 cells developed lung metastasis (Figure 5A).
Slit2-transfected HT1080 cells also formed significantly less pulmonary
metastatic nodules than the parental and control vector–transfected cells
(Figure 5B). Moreover, the size of the metastatic tumor nodules in mice
that were injected with Slit2-transfected HT1080 tumor cells was sig-
nificantly smaller than those of mice that were injected with parental or
control vector–transfected cells (Figure 5C). These results provide evi-
dence that Slit2 inhibits tumor metastasis in our animal models.
To examine the mechanisms by which Slit2 reduces the invasive and
metastatic phenotype of tumors, we detected the expression of keratin-
8/18, E-cadherin (the markers of epithelial phenotype) and N-cadherin
(a marker of mesenchymal phenotype), PCNA (a marker of prolifera-
tion), and Bcl-2 (an antiapoptosis molecule) [22,23]. Results showed
that the number of PCNA-positive cells was significantly lower in
Slit2-transfected than in control vector–transfected HT1080 tumors
(Figure 6, A and B). The expression of keratin-8/18 was remarkably in-
creased, whereas the expression N-cadherin was drastically reduced in
Slit2-transfected compared to vector-transfected HT1080 tumors
(Figure 6C ). The expression of the antiapoptotic molecule Bcl-2 was
also decreased, whereas E-cadherin was not altered (Figure 6C ).
Discussion
In the current study, we have demonstrated that the expression of
Slit2 in human esophageal adenocarcinoma and SCC is reduced com-
pared to normal tissues in a large group of clinical samples. Forced
expression of Slit2 suppresses the growth and metastasis of human fibro-
sarcoma HT1080 and SCC A431 cells in vitro and in animal models.
Our in situ hybridization analysis has shown that the expression of
Slit2 mRNA is decreased in esophageal tumors compared to the nor-
mal tissues and even adjacent normal tissues within tumor samples.
Previous studies showed that Slit2 promoter region was hypermethyl-
ated in colorectal, lung, and breast cancers and gliomas and that the
treatment of these tumor cell lines with demethylating agents increased
the expression of Slit2mRNA [12,13,24,25]. In contrast, Wang et al.
[15] reported that Slit2 expression was increased in some tumors in-
cluding melanoma as assessed by RT-PCR and Western blot analyses
using an anti-Slit2 antibody. One explanation for the discrepancy is
Figure 3. Slit2 enhances tumor apoptosis. (A) Athymic mice were injected subcutaneously with HT1080 tumor cells. Tumors were re-
moved 2 weeks after inoculation, and paraffin-embedded sections were made. Apoptotic cells of tumor samples were determined by
TUNEL assay. The number of apoptotic cells was counted microscopically in five fields. **P < .005. (B) HT1080 tumor tissues were
collected, and tumor lysates were subjected to Western blot analysis. Bcl-xl, Cdk6, and Cyclin D1 were down-regulated in tumors of
mice injected with Slit2-transfected HT1080 cells. (C) The relative levels of proteins in each sample were determined by Quantity one 1-D
Analysis Software and were normalized to GAPDH.
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that Slit2 is expressed constitutively by normal tissues, primarily by
endothelial and epithelial cells [6,7,19]. This is confirmed by in situ
hybridization in the current study (Figure 1A). Tumor samples applied
in the previous report might contain some normal tissues. Therefore,
the Slit2mRNA level in a tumor sample may be affected by the portion
of normal tissues within a tumor sample. In the current study, using
in situ hybridization, direct comparison of cancerous with normal ad-
jacent tissues in tumor samples revealed that Slit2 expression was de-
creased in tumor cells. In our initial experiments examining Slit2
mRNA levels by RT-PCR, virtually all tumor samples expressed Slit2
at different levels (data not shown). In addition, our previous studies
indicated that Slit2 could be up-regulated by inflammatory stimula-
tion [6]. Leukocyte infiltration and inflammation in tumor tissues,
which are common features in tumors, may have effects on the expres-
sion of Slit2 by normal cells in tumor samples. We tried four different
commercially available anti-Slit2 antibodies (Santa Cruz Biotechnology)
to detect Slit2 proteins in human tissues and our Slit2-transfected tumor
lines by immunohistochemical staining. None of them could yield posi-
tive signals (data not shown). Therefore, in situ hybridization technique
provides a direct comparison between normal and cancerous tissues and
may yield more accurate results of Slit2 expression by tumor cells than
detection of Slit2 in whole tumor tissue samples by RT-PCR orWestern
blot. Certainly, application of specific antibodies, when they are avail-
able, will provide further confirmation for the conclusion.
It was reported that the transfection of tumor cells with Slit2 gene
inhibited the colony formation in a selection culturemedium containing
Figure 4. Slit2 inhibits tumor cell migration and invasion. (A) Migration of tumor cells was assessed by wound healing assay. Migration
index was calculated as described in the Materials and Methods section. *P < .001. (B) Invasiveness of tumor cells was determined by
using a two-chamber Matrigel system. Tumor invasion was evaluated at 24 hours after culture. The number of invaded cells was
counted microscopically in 20 (HT1080) or 40 fields (A431). *P < .001.
Figure 5. Slit2 inhibits tumor metastasis in lungs. Athymic mice were injected intravenously with HT1080 tumor cells and lungs were
harvested 4 to 5 weeks later for the assessment of tumor metastasis. Paraffin-embedded lung sections were stained with H&E. Tumor
nodules were evaluated microscopically. (A) Incidence of mice with metastatic tumors in lungs. Data indicate the percentage of mice
with metastatic tumor nodules in lungs (eight mice per group). (B) The number of metastatic tumor nodules per section was counted
microscopically. Analysis of data is based on 24 sections per group (mean ± SEM). **P < .01 compared to both control groups. (C) Size
of metastatic tumor nodules in lungs. Data indicate the average size (diameter) of tumor nodules of eight mice (mean ± SEM). *P < .05
compared to the size of tumor nodules in lungs of mice injected with control vector–transfected cells.
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zeocin [12,13,25]. Moreover, conditioned medium from Slit2- trans-
fected COS-7 cells reduced cell growth and induced apoptosis of colo-
rectal tumor cells [12]. However, it remains to be determined whether
Slit2 affected tumor growth in vivo. Our study indicated that the stable
transfection of tumor cells with Slit2 did inhibit colony formation in
agarose cultures. Most importantly, our data have indicated that in nude
mice, the growth of Slit2-transfected fibrosarcoma HT1080 and SCC
A431 cells is significantly inhibited compared to that of parental or
the control vector–transfected tumor cells. Because our results showed
that most human tumor cells, including HT1080 and A431, expressed
Robo4, Slit2 may mediate effects on tumor cells through interactions
with Robo4. Robo1, 2, and 3 were detected only in a few cell lines (data
not shown). Our ongoing studies will further determine how interac-
tions of Slit2 with Robo4 regulate tumors.
The inhibition of tumor growth by Slit2 transfection is not in con-
sistent to the report by Wang et al. [15] wherein neutralization of
Slit2 inhibited tumor growth. In their report, A375 human melanoma
cells were transfected with a plasmid encoding RoboN, a soluble form
of Robo1 receptor that could bind to Slit2 and block its activities. They
found that transfection with RoboN inhibited tumor growth in nude
mice compared to controls. Furthermore, they found that Slit2 in-
creased the migration of endothelial cells and enhanced angiogenesis
in tumors. Therefore, neutralization of Slit2 by RoboN inhibited an-
giogenesis and suppressed tumor growth [15]. Our study used fibro-
sarcoma HT1080 and SCC A431 cells that originally did not express
Slit2 and differed from the reported study in several ways. First, our
study show that Slit2 has a direct inhibitory effect on tumors as indi-
cated by the reduction of colony formation in the agarose cultures. In
the reported study, Slit2 did not have a direct effect on tumor cells.
Instead, Slit2-mediated effects were to induce the migration of normal
endothelial cells and increase tumor angiogenesis by Slit2-Robo1 sig-
naling. However, conflicting results were reported in a study indicating
that Slit2 inhibited the migration of endothelial cells [26]. In our ex-
periments, we could not detect a significant change in the density of
blood vessels between Slit2-transfected and control tumor tissues (data
not shown). Second, our findings demonstrate that Slit2 affects tumor
invasion and metastasis. This adds support to previous reports indi-
cating that Slit2 inhibited the migration and invasion of tumor cells
in in vitro studies [16,17]. Third, our data show that the number of
PCNA-positive cells, which represents proliferating cells, is signifi-
cantly lower in Slit2-transfected than in control vector–transfected tu-
mors. Finally, it is not excluded that Slit2 may have different effects
Figure 6. Slit2 regulates the expression of molecules related to growth, apoptosis, invasiveness, and metastasis of tumors. Athymic
mice were injected subcutaneously with tumor cells. Tumors were removed 2 weeks after inoculation, and paraffin-embedded sections
were made and stained. (A) Proliferating cells of tumor samples were detected by anti-PCNA antibody. Sections were counterstained
with H&E, and PCNA-positive cells were brown as indicated by arrows in the islets. (B) The number of PCNA-positive cells was counted
microscopically in 10 fields and was statistically analyzed. (C) Keratin-8/18 (Ck8/18), Bcl-2, N-cadherin (N-cad), and E-cadherin (E-cad)
were stained with fluorescence-labeled antibodies (red). Sections were counterstained with a fluorescence DNA dye DAPI (blue).
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on different types of tumor cell lines. Certainly, further studies are re-
quired for clarification of the issue.
Previous reports indicated that conditioned medium from Slit2-
transfected cells induced apoptosis of colorectal tumor cells in cultures
[12]. Although we could not detect a significant increase of apoptosis
in Slit2-transfected tumor cells compared to the controls in cultures,
apoptosis in the tumors of Slit2-transfected HT1080 cells was signifi-
cantly increased (Figure 3A). Moreover, antiapoptotic molecules Bcl-xl
and Bcl2 and cell cycle regulators Cdk 6 and Cyclin D1 were reduced
in Slit2-transfected HT1080 tumors compared to controls. Bcl-xl
belongs to the Bcl-2 family of proteins and has been known to inhibit
apoptosis signal pathways [27,28].Cyclin D1 is a proto-oncogenic reg-
ulator of the G1-S phase checkpoint in the cell cycle, which has been
implicated as a potential oncogene in the pathogenesis of several types
of cancers [29,30]. Cyclin D1 in cooperation with its major catalytic
partners, Cdk4 and Cdk6, facilitates progression through the G1 phase
of the cell cycle. The activity or amount of Cdk6 was reported to be
elevated in cancer cells [31,32]. Our data indicate that Slit2-mediated
regulation of apoptosis and cell cycle signaling pathways may be an
important mechanism for Slit2-induced tumor suppression. Because
cell cycle and apoptosis are closely related, further studies are required
for the dissection of Slit2-mediated specific molecular mechanisms
for the signal pathways.
Tumor metastasis is a process involving complexes of cascade
events, which include migration, invasion, and growth in distal organs
[33]. Our data indicate that Slit2 inhibits the migration and invasion
of fibrosarcoma (HT1080) and SCC (A431). Similar results have been
reported in studies of breast cancer and medulloblastoma cells [16,17],
supporting that Slit2 inhibits the mobility of tumor cells. Further-
more, Slit2 transfection increases the expression of epithelial differ-
entiation markers (keratin 8 and keratin 18) but decreases the level
of mesenchymal marker (N-cadherin) of HT1080 tumors. This indi-
cates that Slit2 suppresses the invasive mesenchymal phenotype of
HT1080 tumors to a less invasive epithelial phenotype, a phenome-
non reported in recent studies [22,23]. Slit2 transfection not only de-
creases the number but also reduces the size of metastatic tumors in
lungs. This implies that Slit2-mediated inhibition of tumor growth
and increase of tumor apoptosis may also be involved in the develop-
ment of metastatic tumor cells in distal organs. Therefore, Slit2 sup-
presses tumor metastasis by a mechanism that involves the regulation
of tumor migration, invasion, apoptosis, and growth.
In summary, our study demonstrates that Slit2 is a tumor-suppressor
gene that inhibits the growth andmetastasis of human fibrosarcoma and
SCC. Slit2 is expressed by normal esophageal tissues, and its expression
level is decreased in esophageal adenocarcinoma and SCC. Introduction
of Slit2 gene into HT1080 and A431 cells, which are defect in Slit2
production, suppresses tumor growth and metastasis in cultures and
in animal models. Furthermore, Slit2 inhibits the expression of anti-
apoptosis and cell cycle signal molecules in tumor cells, which represent
important mechanisms for Slit2-mediated suppression and apoptosis of
tumors. The current studies provide new insights into the mechanisms
of Slit2-mediated effects on tumors, and these may be exploited to new
therapeutic strategies for tumors.
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